Skip to main content
A Singapore Government Agency Website

Conditional approval of Veklury® (remdesivir) for COVID-19 infection in Singapore

The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts, would like to inform healthcare professionals on the conditional approval of Veklury® (remdesivir) for the treatment of COVID-19 patients. Given the urgent public health need during the COVID-19 pandemic, HSA has expedited the review of remdesivir based on its very limited efficacy and safety data and will require more data to be submitted to HSA post-approval to ensure the continued efficacy and safety of the product. To optimise the use of remdesivir in COVID-19 management, the use of Veklury® is currently restricted to Infectious Diseases physicians and guidelines on the appropriate use of remdesivir in healthcare institutions will be developed by MOH and NCID to address the subcategory of patients who are likely to benefit most from the drug. HSA will continue to monitor the benefit-risk profile of Veklury® and provide updates to healthcare professionals as necessary. Healthcare professionals are required to report any suspected serious adverse reactions observed with the use of remdesivir to HSA. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

10 Jun 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.